Promise of monthly oral pill sparks renewed interest in post-exposure prophylaxis (PEP)
Once-weekly islatravir / lenacapavir combination pill maintains HIV viral suppression
Islatravir plus ulonivirine shows promise for weekly oral HIV treatment
Dolutegravir knocks down HIV faster than bictegravir
Long-acting injectable treatment superior to daily pills for adolescents in African trial
Water insecurity nearly quadruples odds of poor HIV outcomes, while hunger and partner violence compound risk in East Africa
Monthly PrEP pill could be made for US$3 a year, but Latin America is shut out of generic licensing
Nearly 200,000 lenacapavir shots given across Africa, but supply issues pose challenges
